Status: Recruiting
Repurposing Valsartan May Protect Against Pulmonary Hypertension
This is a Phase 2, single-center, randomized placebo controlled trial of valsartan (an angiotensin receptor blocker) in adults with pulmonary arterial hypertension. The study will evaluate the safety and clinical efficacy of a 24-week course of valsartan.
Participants needed: 60
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: University of WashingtonUpdated: May 4, 2026Locations: 1
Eligibility criteria
Male or female, age 18 to 80 [+5]
Pregnant or lactating [+10]